Denali Therapeutics (DNLI) Leases (2019 - 2026)

Denali Therapeutics (DNLI) has 8 years of Leases data on file, last reported at $47.6 million in Q1 2026.

• Quarterly Leases fell 5.15% year-over-year to $47.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.6 million (down 5.15% YoY) and the FY2025 annual result came in at $48.5 million, up 2.1% from the prior year.
• Leases retreated to $47.6 million in Q1 2026 per DNLI's latest filing, from $48.5 million in the prior quarter.
• Across five years, Leases topped out at $50.2 million in Q1 2025 and bottomed at $20.0 million in Q3 2025.
• The 5-year median for Leases is $30.0 million (2022), against an average of $33.7 million.
• Peak annual rise in Leases reached 98.34% in 2025, while the deepest fall reached 15.52% in 2025.
• Tracing DNLI's Leases over 5 years: stood at $30.4 million in 2022, then decreased by 12.11% to $26.8 million in 2023, then surged by 77.69% to $47.5 million in 2024, then gained by 2.1% to $48.5 million in 2025, then retreated by 1.89% to $47.6 million in 2026.
• Per Business Quant, the three latest DNLI Leases figures stand at $47.6 million (Q1 2026), $48.5 million (Q4 2025), and $20.0 million (Q3 2025).

Peer Comparison